Citations

Clear

16281 citation(s) found for "Yu, David".

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Jain, Michael D. , Spiegel, Jay Y. , Nastoupil, Loretta J. , Tamaresis, John , Ghobadi, Armin , Lin, Yi , Lekakis, Lazaros J. , Oluwole, Olalekan O. , McGuirk, Joseph P. , Deol, Abhinav , Dorritie, Kathleen , Sehgal, Alison R. , Hill, Brian T. , Ulrickson, Matthew L. , Patel, Dilan A. , Jacobs, Miriam T. , Bansal, Radhika , Patel, Vivek , Rapoport, Aaron P. , Neelapu, Sattva S. , Lunning, Matthew A. , Dahiya, Saurabh , Oluwole, Olalekan O , McGuirk, Joseph , Deol, Abhinav , Goy, Andre Henri , Munoz, Javier L , Ulrickson, Matthew , Westin, Jason R , Chavez, Julio C , Patel, Dilan , Jacobs, Miriam T , Bansal, Radhika , Bennani, N Nora , Rapoport, Aaron P , Vose, Julie , Miklos, David B , Neelapu, Sattva S , Locke, Frederick L , Dahiya, Saurabh , Jain, Michael D , Lin, Yi , Nastoupil, Loretta J , Ghobadi, Armin , Reagan, Patrick Michael , Andreadis, Charalambos Babis , Muñoz, Javier , Westin, Jason R. , Bennani, N. Nora , Vose, Julie M. , Miklos, David B. , Locke, Frederick L.

Mayo Clinic

Journal of Clinical Oncology | August 2, 2024 | Volume: 42 | Issue: 30 | Pages: 3581-3592

10.1200/jco.23.02786 | PMID 39094076 Get It

PURPOSE Axicabtagene ciloleucel (axi-cel) is an autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that is approved for the treatment of relapsed or refractory large B-cell lymphoma. Little is known about the long-term survivorship after CAR T-cell therapy. METHODS We previously reported the results of 298 patients who were leukapheresed with the intent to receive standard-of-care axi-cel (n = 275 infused) after two or more previous lines of therapy at a median follow-up of 12.9 months. Here, we report extended follow-up of this cohort to a median of 58 months, with a focus on late survivorship events. RESULTS Among axi-cel–infused patients, progression-free survival at 5 years was 29% and overall survival (OS) at 5 years was 40%. The 5-year lymphoma-specific survival was 53% with infrequent late relapses. However, the 5-year nonrelapse mortality (NRM) was 16.2%, with over half of NRM events occurring beyond 2 years. Patients who were 60 years and older had a lower risk of relapse ( P = .02), but a higher risk of NRM compared with patients younger than 60 years (NRM odds ratio, 4.5 [95% CI, 2.1 to 10.8]; P < .001). Late NRM was mainly due to infections and subsequent malignant neoplasms (SMNs). In total, SMNs occurred in 24 patients (9%), including therapy-related myeloid neoplasms (n = 15), solid tumors (n = 7), and unrelated lymphoid malignancies (n = 2). CONCLUSION In the standard-of-care setting, axi-cel exhibits outcomes consistent with those reported in clinical trials, with sustained, durable responses observed at the 5-year time point. However, late infections and the development of SMN are key survivorship issues that reduce long-term survival after CAR T-cell therapy, particularly in the elderly.
Revision total elbow arthroplasty is associated with a high rate of 30-day complications: A descriptive analysis of a national database
El-Najjar, Dany , Gupta, Puneet , Peterson, Joel R. , Rogalski, Brandon L. , Levine, William N. , Gupta, Puneet , Marigi, Erick M. , El-Najjar, Dany B , Mehta, Apoorva , Trofa, David P , Jobin, Charles M.

Mayo Clinic

Shoulder & Elbow | August 2, 2024 | Volume: 17 | Issue: 5 | Pages: 634-640

10.1177/17585732241269001 | PMID 39552697 Get It

Introduction Revision total elbow arthroplasty (TEA) is indicated for component loosening, periprosthetic joint infection, and fractures. Previous investigations into revision TEA complications have small sample sizes and limited exploration of acute complications. This study aims to characterize the 30-day complications and associated demographics of patients undergoing revision TEA using a large national database. Methods The 2015–2020 American College of Surgeons National Surgical Quality Improvement Program database was used to identify all revision TEA patients. Results The analysis included 158 patients (average age 62.6 years). The overall complication rate was 13.9% ( n = 22). The most common 30-day complications were organ/space surgical site infection (3.8%, n = 6), unplanned readmission (3.2%, n = 5), intraoperative or postoperative transfusion (3.2%, n = 5), and unplanned reoperation (1.9%, n = 3). Patients with a history of dyspnea or steroid/immunosuppressant use for a chronic condition had significantly higher rates of bleeding requiring transfusion ( p = .029 and p = .021, respectively). Additionally, patients aged 80 years or older had a significantly higher rate of unplanned readmission ( p = .032). Conclusion Revision TEA has a 13.9% rate of complications within 30-days of surgery, with most involving surgical site infection, unplanned readmission, and blood transfusion. Level of Evidence IV.
Pulsed Vibro-Acoustic Analysis Technique for Monitoring Bone Health in Preterm Infants: A Pilot Study
Chaudhary, Pradeep Kumar , Rosen, David , Larson, Nicholas B. , Brumbaugh, Jane E. , Fatemi, Mostafa , Gu, Juanjuan, Rosen, David P , Fatemi, Mostafa , Larson, Nicholas B , Brumbaugh, Jane E , Gu, Juanjuan , Alizad, Azra

Mayo Clinic

IEEE Access | August 2, 2024 | Volume: 12 | Issue: No issue available | Pages: 106707-106719

10.1109/access.2024.3437375 | PMID 39148928 Get It

Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: a phase II PRECAM experimental study
Lai, Chuanxi , Lv, Yiming , Zhang, Feixiang , Shi, Liming , Wang, Yunfei , Shen, Yanbin , Xu, Lingna , Hu, Peng , Tang, Wen, Xu, Dengyong, Cao, Gaoyang , Shan, Lina , Jia, Xiya, Chen, Yiyi , Wang, Da , Lao, Weifeng , Sun, Xiaonan , Wang, Fei , Hu, Peng, Larson, David W. , Gu, Hongcang , Huang, Xuefeng , Dai, Sheng

Mayo Clinic

International Journal of Surgery | August 2, 2024 | Volume: 111 | Issue: 1 | Pages: 334-345

10.1097/js9.0000000000001960 | PMID 39093871 Get It

Background: Conventional neoadjuvant chemoradiotherapy (nCRT) yields a pathologic complete response (pCR) rate of 15–30% for locally advanced rectal cancer (LARC). This study ventures to shift this paradigm by incorporating short-course nCRT with immunotherapy, specifically Envafolimab, to achieve improved treatment efficacy and possibly redefine the standard of care for LARC. Materials and methods: The PRECAM study is a prospective, single-arm, phase 2 clinical trial for LARC in patients with microsatellite stable (MSS) tumors. Participants received short-course radiotherapy (25Gy/5f), followed by two cycles of CAPEOX chemotherapy and six weekly doses of Envafolimab, a PD-L1 antibody, before total mesorectal excision surgery. The primary endpoint was the pCR rate. Results: From April to December 2022, 34 patients were enrolled, of whom 32 completed the study, each diagnosed with an MSS rectal adenocarcinoma. All patients underwent preoperative CRT combined with Envafolimab. Remarkably, a pCR rate of 62.5% (20/32) was attained, and a significant pathologic response rate of 75% (24/32) was achieved. Additionally, 21 of 32 participants achieved a neoadjuvant rectal (NAR) score below 8, suggesting an effective treatment response. Common adverse events included tenesmus (78.1%), diarrhea (62.5%), and leukocyte decrease (40.6%). Two Grade 3 adverse events were noted, one related to liver function abnormality and the other to a decrease in platelet count. Surgical procedures were performed in all cases, with minor complications, including ileus, infections, and anastomotic leakage. As of this report, there have been no reported cases of recurrence or death during the follow-up period, ranging from 12 to 20 months. Conclusion: In LARC patients exhibiting MSS tumors, combining short-course nCRT with Envafolimab demonstrated favorable efficacy, leading to a significant pCR rate. Minor adverse effects and surgical complications were observed. These preliminary but promising results underscore the potential of this approach and call for further exploration and validation through a randomized controlled trial.
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
Aldoss, Ibrahim , Roloff, Gregory W. , Kopmar, Noam E. , Lin, Chenyu , Advani, Anjali S. , Dekker, Simone E. , O’Connor, Timothy E. , Jeyakumar, Nikeshan , Muhsen, Ibrahim N. , Valtis, Yannis K. , Zhang, Amy , Miller, Katharine, Sutherland, Katherine C. , Ahmed, Mohamed , Zambrano, Héctor, Bradshaw, Danielle , Schwartz, Marc S. , Tracy, Sean , Kubiak, Michal Jakub , Mukherjee, Akash , Mountjoy, Luke , Malik, Shahbaz A. , Shaughnessy, Paul , Ladha, Abdullah , Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T. , Moore, Jozal , Connor, Matthew P. , O’Dwyer, Kristen M. , Hill, LaQuisa C. , Tsai, Stephanie B., Sasine, Joshua , Solh, Melhem , Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Oliai, Caspian , Park, Jae H. , Bachanová, Veronika , Galal, Ahmed , Bishop, Michael R. , Pullarkat, Vinod , Muffly, Lori , Lin, Chenyu , Advani, Anjali S , Jeyakumar, Nikeshan , Dykes, Kaitlyn C , Chen, Evan , Bradshaw, Danielle , Dholaria, Bhagirathbhai R , Majhail, Navneet S , Logan, Aaron C , Ladha, Abdullah , Hilal, Talal , Moore, Jozal , Connor, Matthew , Hill, LaQuisa C , Sasine, Joshua , Lee, Catherine J , Leonard, Jessica T , Frey, Noelle V , Luskin, Marlise R , Muffly, Lori , Bachanova, Veronika , Aldoss, Ibrahim , Muhsen, Ibrahim N , Sutherland, Katherine , Roloff, Gregory W , Faramand, Rawan , Gupta, Vishal , Dykes, Kaitlyn C. , Mercadal, Santiago , Schwartz, Marc, Dholaria, Bhagirathbhai , Majhail, Navneet S. , Battiwalla, Minoo , Mathews, John, Hilal, Talal , O'Dwyer, Kristin , Tsai, Stephanie B., Kota, Vamsi , Oliai, Caspian H , Frey, Noelle V. , Bishop, Michael Russell , Stock, Wendy , Cassaday, Ryan D. , Shah, Bijal

Mayo Clinic

Blood Advances | August 2, 2024 | Volume: 8 | Issue: 23 | Pages: 6139-6147

10.1182/bloodadvances.2024013747 | PMID 39093952 Get It

Abstract The effect of prior inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes remains unclear in adults with acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter analysis of 189 patients with relapsed/refractory ALL treated with brexu-cel. Over half of the patients received InO before brexu-cel (InO exposed). InO-exposed patients were more heavily pretreated (P = .02) and frequently had active marrow disease before apheresis (P = .03). Response rate and toxicity profile after brexu-cel were comparable for InO-exposed and InO-naïve patients; however, consolidation therapy after brexu-cel response was used at a higher rate in InO-naïve patients (P = .005). With a median follow-up of 11.4 months, InO-exposed patients had inferior progression-free survival (PFS; P = .013) and overall survival (OS; P = .006) in univariate analyses; however, prior InO exposure did not influence PFS (hazard ratio, 1.20; 95% confidence interval, 0.71-2.03) in multivariate models. Within InO-exposed patients, InO responders had superior PFS (P = .002) and OS (P &lt; .0001) relative to InO-refractory patients. The timing of administering InO did not affect brexu-cel outcomes, with comparable PFS (P = .51) and OS (P = .86) for patients receiving InO as bridging therapy or before apheresis. In conclusion, although InO exposure was associated with inferior survival outcomes after brexu-cel in unadjusted analyses, these associations were no longer significant in multivariate analyses, suggesting it is unlikely that InO negatively affects brexu-cel efficacy. Our data instead imply that InO-exposed recipients of brexu-cel tend to be higher-risk patients with intrinsic adverse leukemia biology.
Gender Differences in Autonomy Granted to Residents and Fellows During Procedural Training: A Systematic Review and Meta-Analysis
Lund, Sarah , Griffeth, Elaine M. , Williamson, Andrea J.H. , Collings, Amelia T. , Gudmundsdottir, Hallbera , Han, Amy , Kearse, LaDonna , Kratzke, Ian M. , Wilkins, Parvathi , Prokop, Larry J. , Cook, David A. , Williamson, Andrea , Collings, Amelia , Prokop, Larry , Kearse, LaDonna E , Gudmundsdottir, Hallbera

Mayo Clinic

Academic Medicine | August 2, 2024 | Volume: 99 | Issue: 8 | Pages: 922-930

10.1097/acm.0000000000005673 | PMID 38412483 Get It

Abstract Purpose Supervisors may be prone to implicit (unintentional) bias when granting procedural autonomy to trainees due to the subjectivity of autonomy decisions. The authors aimed to conduct a systematic review and meta-analysis to assess the differences in perceptions of procedural autonomy granted to physician trainees based on gender and/or race. Method MEDLINE, Embase, CENTRAL, Scopus, and Web of Science were searched (search date: January 5, 2022) for studies reporting quantitative gender- or race-based differences in perceptions of procedural autonomy of physician trainees. Reviewers worked in duplicate for article selection and data abstraction. Primary measures of interest were self-reported and observer-rated procedural autonomy. Meta-analysis pooled differences in perceptions of procedural autonomy based on trainee gender. Results The search returned 2,714 articles, of which 16 were eligible for inclusion. These reported data for 6,109 trainees (median, 90 per study) and 2,763 supervisors (median, 54 per study). No studies investigated differences in perceptions of autonomy based on race. In meta-analysis of disparities between genders in autonomy ratings (positive number favoring female trainees), pooled standardized mean differences were −0.12 (95% confidence interval [CI], −0.19 to −0.04; P = .003; n = 10 studies) for trainee self-rated autonomy and −0.05 (95% CI, −0.11 to 0.01; P = .07; n = 9 studies) for supervisor ratings of autonomy. Conclusions Limited evidence suggests that female trainees perceived that they received less procedural autonomy than did males. Further research exploring the degree of gender- and race-based differences in procedural autonomy, and factors that influence these differences is warranted.
Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction
Barbier, Emilie, Burmeister, Bryan , Cunningham, David , Grilli, Maurizio , Hofheinz, Ralf‐Dieter , Kieser, Meinhard , Langley, Ruth E. , Lordick, Florian , Mauer, Murielle , Michalski, Christoph , Nankivell, Matthew , Stahl, Michael , Urba, Susan G., Lanschot, Jan van, Vordermark, Dirk , Walsh, T. N. , Proctor, Tanja, Vey, Johannes A. , Cunningham, David , Ronellenfitsch, Ulrich , Friedrichs, Juliane , Bass, Gary Alan , Eyck, Ben M. , Kleeff, Jorg H. , Klevebro, Fredrik , Lutz, Manfred Paul , Michl, Patrick , Nilsson, Magnus , Seide, Svenja , Shah, Manish A , Shi, Qian , Ychou, Marc

Mayo Clinic

JAMA Network Open | August 2, 2024 | Volume: 7 | Issue: 8 | Pages: e2425581

10.1001/jamanetworkopen.2024.25581 | PMID 39093560 Get It

ImportanceThe prognosis of patients with adenocarcinoma of the esophagus and esophagogastric junction (AEG) is poor. From current evidence, it remains unclear to what extent preoperative chemoradiotherapy (CRT) or preoperative and/or perioperative chemotherapy achieve better outcomes than surgery alone.ObjectiveTo assess the association of preoperative CRT and preoperative and/or perioperative chemotherapy in patients with AEG with overall survival and other outcomes.Data SourcesLiterature search in PubMed, Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, ClinicalTrials.gov, and International Clinical Trials Registry Platform was performed from inception to April 21, 2023.Study SelectionTwo blinded reviewers screened for randomized clinical trials comparing preoperative CRT plus surgery with preoperative and/or perioperative chemotherapy plus surgery, 1 intervention with surgery alone, or all 3 treatments. Only data from participants with AEG were included from trials that encompassed mixed histology or gastric cancer. Among 2768 initially identified studies, 17 (0.6%) met the selection criteria.Data Extraction and SynthesisThe Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines were followed for extracting data and assessing data quality by 2 independent extractors. A bayesian network meta-analysis was conducted using the 2-stage approach.Main Outcomes and MeasuresOverall and disease-free survival, postoperative morbidity, and mortality.ResultsThe analyses included 2549 patients (2206 [86.5%] male; mean [SD] age, 61.0 [9.4] years) from 17 trials (conducted from 1989-2016). Both preoperative CRT plus surgery (hazard ratio [HR], 0.75 [95% credible interval (CrI), 0.62-0.90]; 3-year difference, 105 deaths per 1000 patients) and preoperative and/or perioperative chemotherapy plus surgery (HR, 0.78 [95% CrI, 0.64-0.91]; 3-year difference, 90 deaths per 1000 patients) showed longer overall survival than surgery alone. Comparing the 2 modalities yielded similar overall survival (HR, 1.04 [95% CrI], 0.83-1.28]; 3-year difference, 15 deaths per 1000 patients fewer for CRT). Similarly, disease-free survival was longer for both modalities compared with surgery alone. Postoperative morbidity was more frequent after CRT plus surgery (odds ratio [OR], 2.94 [95% CrI, 1.01-8.59]) than surgery alone. Postoperative mortality was not significantly more frequent after CRT plus surgery than surgery alone (OR, 2.50 [95% CrI, 0.66-10.56]) or after chemotherapy plus surgery than CRT plus surgery (OR, 0.44 [95% CrI, 0.08-2.00]).Conclusions and RelevanceIn this meta-analysis of patients with AEG, both preoperative CRT and preoperative and/or perioperative chemotherapy were associated with longer survival without relevant differences between the 2 modalities. Thus, either of the 2 treatments may be recommended to patients.
Coordinated Targeting of S6K1/2 and AXL Disrupts Pyrimidine Biosynthesis in PTEN-Deficient Glioblastoma
Behrmann, Catherine A. , Ennis, Kelli N. , Sarma, P.N. , Wetzel, Collin , Clark, Nicholas A. , Handorf, Kate M. Von , Vallabhapurapu, Subrahmanya , Andreani, Cristina , Reigle, James , Czyzyk-Krzeska, Maria , Kendler, Ady , Sengupta, Soma , Dasgupta, Biplab , Plas, David R. , Sarma, Pranjal , Von Handorf, Kate M , Scaglioni, Pier Paolo , Meller, Jarek , Czyzyk-Krzeska, Maria F , Kendler, Ady , Qi, Xiaoyang , Sarkaria, Jann N , Medvedovic, Mario , Sengupta, Soma , Dasgupta, Biplab , Plas, David R , Qi, Xiaoyang , Sarkaria, Jann N.

Mayo Clinic

Cancer Research Communications | August 1, 2024 | Volume: 4 | Issue: 8 | Pages: 2215-2227

10.1158/2767-9764.crc-23-0631 | PMID 39087397 Get It

Abstract Intrinsic resistance to targeted therapeutics in PTEN-deficient glioblastoma (GBM) is mediated by redundant signaling networks that sustain critical metabolic functions. Here, we demonstrate that coordinated inhibition of the ribosomal protein S6 kinase 1 (S6K1) and the receptor tyrosine kinase AXL using LY-2584702 and BMS-777607 can overcome network redundancy to reduce GBM tumor growth. This combination of S6K1 and AXL inhibition suppressed glucose flux to pyrimidine biosynthesis. Genetic inactivation studies to map the signaling network indicated that both S6K1 and S6K2 transmit growth signals in PTEN-deficient GBM. Kinome-wide ATP binding analysis in inhibitor-treated cells revealed that LY-2584702 directly inhibited S6K1, and substrate phosphorylation studies showed that BMS-777607 inactivation of upstream AXL collaborated to reduce S6K2-mediated signal transduction. Thus, combination targeting of S6K1 and AXL provides a kinase-directed therapeutic approach that circumvents signal transduction redundancy to interrupt metabolic function and reduce growth of PTEN-deficient GBM. Significance: Therapy for glioblastoma would be advanced by incorporating molecularly targeted kinase-directed agents, similar to standard of care strategies in other tumor types. Here, we identify a kinase targeting approach to inhibit the metabolism and growth of glioblastoma.
Navigating Progress: 8-Year Single-Center Experience With Minimally Invasive Proctectomy and IPAA
Violante, Tommaso , Ferrari, Davide , Mathis, Kellie L. , Behm, Kevin T. , Shawki, Sherief , Dozois, Eric J. , Cima, Robert R. , Larson, David W. , Violante, Tommaso , Larson, David W , Cima, Robert , Ferrari, Davide

Mayo Clinic

Diseases of the Colon & Rectum | August 1, 2024 | Volume: 67 | Issue: 11 | Pages: 1437-1442

10.1097/dcr.0000000000003465 | PMID 39087676 Get It

BACKGROUND: IPAA has become the criterion standard for treating ulcerative colitis, familial adenomatous polyposis, and selected cases of Crohn’s colitis. Robotic surgery promises improved postoperative outcomes and decreased length of stay. However, few studies have evaluated the benefits of robotic IPAA compared to laparoscopy. OBJECTIVE: To compare short-term 30-day postoperative outcomes of robotic versus laparoscopic proctectomy with IPAA and diverting loop ileostomy. DESIGN: Retrospective observational study from a single, high-volume center. SETTINGS: Mayo Clinic, Rochester, Minnesota (tertiary referral center for IBD). PATIENTS: All adult patients undergoing minimally invasive proctectomy with IPAA and diverting loop ileostomy between January 2015 and April 2023. MAIN OUTCOME MEASURES: Thirty-day complications, hospital length of stay, estimated blood loss, conversion rate, 30-day readmission, and 30-day reoperation. RESULTS: Two hundred seventeen patients were included in the study; 107 underwent robotic proctectomy with IPAA and diverting loop ileostomy, whereas 110 had laparoscopic proctectomy with IPAA and diverting loop ileostomy. Operating time was significantly longer in the robotic group (263 ± 38 vs 228 ± 75 minutes, p < 0.0001). The robotic group also had lower estimated blood loss (81.5 ± 77.7 vs 126.8 ± 111.0 mL, p = 0.0006) as well as fewer conversions (0% vs 8.2%, p = 0.003). Patients in the robotic group received more intraoperative fluids (3099 ± 1140 vs 2472 ± 996 mL, p = 0.0001). However, there was no difference in length of stay, 30-day morbidity, 30-day readmission, 30-day reoperation, rate of diverting loop ileostomy closure at 3 months, and surgical IPAA complication rate after ileostomy closure. LIMITATIONS: Retrospective design, single-center study, potential bias because of the novelty of the robotic approach, and lack of long-term and quality-of-life outcomes. CONCLUSIONS: Robotic proctectomy with IPAA and diverting loop ileostomy may offer advantages in terms of estimated blood loss and conversion rate while maintaining the benefits of minimally invasive surgery. Further research is needed to evaluate long-term outcomes. See Video Abstract. NAVEGANDO EL PROGRESO: EXPERIENCIA DE OCHO AÑOS EN UN SOLO CENTRO CON PROCTECTOMÍA MÍNIMAMENTE INVASIVA Y ANASTOMOSIS ANAL-BOLSA ILEAL ANTECEDENTES: La anastomosis anal-bolsa ileal (IPAA) se ha convertido en el estándar de oro para el tratamiento de la colitis ulcerosa, la poliposis adenomatosa familiar y casos seleccionados de colitis de Crohn. La cirugía robótica promete mejores resultados posoperatorios y una menor duración de la estancia hospitalaria. Sin embargo, pocos estudios han evaluado los beneficios de la IPAA robótica en comparación con la laparoscopia. OBJETIVO: Comparar los resultados postoperatorios a corto plazo a 30 días de la proctectomía robótica versus laparoscópica con IPAA e ileostomía en asa de derivación. DISEÑO: Estudio observacional retrospectivo de un único centro de gran volumen. AJUSTES: Mayo Clinic, Rochester, Minnesota (centro terciario de referencia para EII). PACIENTES: Todos los pacientes adultos sometidos a proctectomía mínimamente invasiva con IPAA y DLI entre Enero de 2015 y Abril de 2023. PRINCIPALES MEDIDAS DE RESULTADOS: Complicaciones a los 30 días, duración de la estancia hospitalaria, pérdida de sangre estimada, tasa de conversión, reingreso a los 30 días y reoperación a los 30 días. RESULTADOS: Se incluyeron en el estudio 217 pacientes; 107 se sometieron a proctectomía robótica con IPAA y DLI, mientras que 110 se sometieron a proctectomía laparoscópica con IPAA y DLI. El tiempo operatorio fue significativamente mayor en el grupo robótico (263 ± 38 minutos versus 228 ± 75 minutos, p < 0,0001); la pérdida de sangre estimada (EBL) fue menor en el grupo robótico (81,5 ± 77,7 ml versus 126,8 ± 111,0 ml, p = 0,0006), así como el número de conversiones (0% versus 8,2%, p = 0,003). Los pacientes del grupo robótico recibieron más líquidos intraoperatorios (3099 ± 1140 ml versus 2472 ± 996 ml, p = 0,0001). Sin embargo, no hubo diferencias en la duración de la estancia hospitalaria, la morbilidad a los 30 días, el reingreso a los 30 días, la reoperación a los 30 días, la tasa de cierre del DLI a los tres meses y la tasa de complicaciones quirúrgicas de la IPAA después del cierre de la ileostomía. LIMITACIONES: Diseño retrospectivo, estudio unicéntrico, posible sesgo debido a la novedad del enfoque robótico, falta de resultados a largo plazo y de calidad de vida. CONCLUSIONES: La proctectomía robótica con IPAA y DLI puede ofrecer ventajas en términos de EBL y tasa de conversión, manteniendo al mismo tiempo los beneficios de la cirugía mínimamente invasiva. Se necesita más investigación para evaluar los resultados a largo plazo. (Traducción—Dr. Yesenia Rojas-Khalil)
Recurrence of Non–Small Cell Lung Cancer With Visceral Pleural Invasion
Wang, Xiaofei , Damman, Bryce , Wigle, Dennis A. , Port, Jeffrey L., Ashrafi, Ahmad S., Liberman, Moïshe , Landreneau, Rodney J., Yasufuku, Kazuhiro, Yang, Stephen C. , Mitchell, John D. , Keenan, Robert J. , Miller, Daniel P. , Kozono, David , Mentlick, Jennifer, Vokes, Everett E., Stinchcombe, Thomas E. , Wigle, Dennis, Kozono, David E , Altorki, Nasser Khaled , Jones, David R. , Conti, Massimo , BAUER, THOMAS L , Miller, Daniel, Vokes, Everett E.

Mayo Clinic

JAMA Oncology | August 1, 2024 | Volume: 10 | Issue: 9 | Pages: 1179

10.1001/jamaoncol.2024.2491 | PMID 39088196 Get It

Importance The randomized clinical trial Cancer and Leukemia Group B (CALGB) 140503 showed that for patients with clinically staged T1N0 non–small cell lung cancer (NSCLC; ≤2 cm), sublobar resections were associated with similar oncological outcomes to those after lobar resection. The association of the extent of parenchymal resection with recurrence and survival in patients with tumors pathologically upstaged to T2 based on visceral pleural invasion (VPI) is controversial. Objective To determine survival and recurrence rates in patients with small peripheral pT2 NSCLC (≤2 cm) that was treated by either lobar or sublobar resection in CALGB 140503. Design, Participants, and Setting CALGB 140503, a randomized multicenter noninferiority trial, included 697 patients with small peripheral NSCLC that was clinically staged as T1N0. Enrollment was from June 2007 through March 2017 at 83 participating institutions, and after a median follow-up of 7 years, the primary outcome of disease-free survival after sublobar resection was noninferior to that after lobar resection. Intervention Lobar or sublobar resection. Main Outcomes and Measures Survival end points were estimated by the Kaplan-Meier estimator. Hazard ratios and 95% CIs were estimated using stratified Cox proportional hazard models. Results Of 679 participants, 390 (57.4%) were female, and the median (range) age was 67.8 (37.8-89.7) years. Among 697 patients randomized, 566 (81.2%) had pT1 tumors (no VPI) and 113 (16.2%) had pT2 tumors (VPI). Five-year disease-free survival was 65.9% (95% CI, 61.9%-70.2%) in patients with pT1 compared with 53.3% (95% CI, 44.3%-64.1%) in patients with pT2 tumors (stratified log-rank: P = .02). Disease recurrence developed in 27.6% of patients with pT1 (locoregional only: 60 [10.8%]; distant only: 81 [14.6%]) and 41.6% of those with pT2 (locoregional only: 17 [15.0%]; distant only: 27 [23.9%]). Five-year recurrence-free survival was 73.1% (95% CI, 69.2%-77.1%) for pT1 tumors and 58.2% (95% CI, 49.2%-68.8%) for pT2 tumors (stratified log-rank: P = .01). There were no intergroup differences in disease-free or recurrence-free survival based on the extent of parenchymal resection. Conclusions and Relevance The results of this secondary analysis suggest that compared with patients with tumors without VPI, patients who had tumors with VPI had worse disease-free and recurrence-free survival and a higher rate of local and distant disease recurrence. These high rates of recurrence were independent of the extent of parenchymal resection, and these data support the inclusion of these patients in adjuvant therapy trials. Trial Registration ClinicalTrials.gov Identifier: NCT0049933